MavriX Bio Announces First Patient Dosed in ASCEND-AS Trial of MVX-220, Investigational Gene Therapy for Angelman Syndrome
-First Gene Therapy Trial for Angelman Syndrome -Orphan Drug Designation Granted for MVX-220 MIDDLETON, Mass., Nov. 6, 2025 /PRNewswire/ — MavriX Bio, a clinical-stage... Read more.
Eilean Therapeutics to Present First-in-Class, Wild-Type-Sparing JAK2-JH2/V617F Inhibitor ZE74-0282 at ASH 2025 and Initiate Clinical Studies in December 2025
DOVER, Del., Nov. 6, 2025 /PRNewswire/ — Eilean Therapeutics LLC, a biotechnology company developing next-generation precision medicines for cancer and immune-inflammatory... Read more.
ATDev Joins $41 Million ARPA-H Initiative to Build the Future of Robotic Mobility and Independence
PITTSBURGH, Nov. 6, 2025 /PRNewswire/ — Assistive Technology Development, Inc. (ATDev) announced today that it is a subcontractor for the Robotic Assistive... Read more.
STAGWELL INC. (NASDAQ: STGW) REPORTS RESULTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025
Q3 YoY Revenue Growth of 4%, Q3 YoY Net Revenue Growth of 6% Q3 YoY Net Revenue Growth excluding Advocacy of 10%, Digital Transformation Net Revenue Growth of 12%,... Read more.
ResumeBuilder.com Survey: 1 in 3 Dating App Users Are Swiping for Jobs, Not Love
Many users are leveraging dating apps for networking, mentorship, and even job offers GUAYNABO, Puerto Rico, Nov. 6, 2025 /PRNewswire/ — ResumeBuilder.com,... Read more.
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025
VENTURE Study Exploratory Analysis Shows VK2735 Improved Cardiometabolic Parameters After 13 Weeks; Reducing Prediabetes and Metabolic Syndrome SAN DIEGO, Nov. 6,... Read more.
REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights
RGX-202 program for Duchenne muscular dystrophy advancing rapidly, topline results expected early Q2 2026 and BLA submission mid-2026 Pivotal trial enrollment completed... Read more.
Tripadvisor, Inc. Earnings Press Release Available on Company’s Investor Relations Site
NEEDHAM, Mass., Nov. 6, 2025 /PRNewswire/ — Tripadvisor, Inc. (NASDAQ: TRIP) issued its third quarter 2025 earnings press release which is available now at... Read more.
Mwyngil Therapeutics Announces In-Licensing of GPR75 Modulators and Cell-Surface Discovery Platform from Expert Systems Inc.
DOVER, Del., Nov. 6, 2025 /PRNewswire/ — Mwyngil Therapeutics Inc., a biopharmaceutical company dedicated to developing first-in-class and best-in-class small-molecule... Read more.
CaneToadium-WLCP Introduces Global Blockchain Endowment Model for Transparent Wildlife Conservation
GOLD COAST, Australia, Nov. 6, 2025 /PRNewswire/ — The CaneToadium-WLCP Wildlife and Conservation Project has officially announced the global introduction... Read more.